Your browser doesn't support javascript.
loading
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity.
Wichroski, Michael; Benci, Joseph; Liu, Si-Qi; Chupak, Louis; Fang, Jie; Cao, Carolyn; Wang, Cindy; Onorato, Joelle; Qiu, Hongchen; Shan, Yongli; Banas, Dana; Powles, Ryan; Locke, Gregory; Witt, Abigail; Stromko, Caitlyn; Qi, Huilin; Zheng, Xiaofan; Martin, Scott; Ding, Min; Gentles, Robert; Meanwell, Nicholas; Velaparthi, Upender; Olson, Richard; Wee, Susan; Tenney, Daniel; Parker, Christopher G; Cravatt, Benjamin F; Lawrence, Michael; Borzilleri, Robert; Lees, Emma.
Afiliación
  • Wichroski M; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Benci J; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Liu SQ; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Chupak L; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Fang J; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Cao C; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Wang C; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Onorato J; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Qiu H; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Shan Y; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Banas D; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Powles R; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Locke G; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Witt A; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Stromko C; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Qi H; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Zheng X; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Martin S; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Ding M; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Gentles R; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Meanwell N; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Velaparthi U; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Olson R; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
  • Wee S; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Tenney D; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Parker CG; Department of Chemistry, Scripps Research Institute, La Jolla, CA 92037, USA.
  • Cravatt BF; Department of Chemistry, Scripps Research Institute, La Jolla, CA 92037, USA.
  • Lawrence M; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Borzilleri R; Research and Development, Bristol Myers Squibb Company, Lawrenceville, NJ 08648, USA.
  • Lees E; Research and Development, Bristol Myers Squibb Company, Cambridge, MA 02142, USA.
Sci Transl Med ; 15(719): eadh1892, 2023 10 25.
Article en En | MEDLINE | ID: mdl-37878674
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Receptor de Muerte Celular Programada 1 / Neoplasias Límite: Animals / Humans Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Receptor de Muerte Celular Programada 1 / Neoplasias Límite: Animals / Humans Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos